Vocal expression of emotions discriminates dementia with Lewy bodies from Alzheimer’s disease
https://doi.org/10.1002/dad2.12594
Abstract
Dementia with Lewy bodies (DLB) and Alzheimer's disease (AD), the two most common neurodegenerative dementias, both exhibit altered emotional processing. However, how vocal emotional expressions alter in and differ between DLB and AD remains uninvestigated. We collected voice data during story reading from 152 older adults comprising DLB, AD, and cognitively unimpaired (CU) groups and compared their emotional prosody in terms of valence and arousal dimensions. Compared with matched AD and CU participants, DLB patients showed reduced overall emotional expressiveness, as well as lower valence (more negative) and lower arousal (calmer), the extent of which was associated with cognitive impairment and insular atrophy. Classification models using vocal features discriminated DLB from AD and CU with an AUC of 0.83 and 0.78, respectively. Our findings may aid in discriminating DLB patients from AD and CU individuals, serving as a surrogate marker for clinical and neuropathological changes in DLB. Highlights DLB showed distinctive reduction in vocal expression of emotions. Cognitive impairment was associated with reduced vocal emotional expression in DLB. Insular atrophy was associated with reduced vocal emotional expression in DLB. Emotional expression measures successfully differentiated DLB from AD or controls. Vocal expression of emotions discriminates dementia with Lewy bodies from Alzheimer's disease.
Highlights DLB showed distinctive reduction in vocal expression of emotions. Cognitive impairment was associated with reduced vocal emotional expression in DLB. Insular atrophy was associated with reduced vocal emotional expression in DLB. Emotional expression measures successfully differentiated DLB from AD or controls. Vocal expression of emotions discriminates dementia with Lewy bodies from Alzheimer's disease.
Corporate Initiatives
AI-based clinical decision support platform
Glass Health is an AI-based clinical decision support (CDS) platform developed by Czech company Board of Innovation.
The system helps with clinical reasoning and quickly suggests differential diagnoses and treatment plans. By inputting the patient's symptoms and information, Glass Health's AI provides useful recommendations for doctors and supports clinical decision-making. The goal is to improve efficiency in the medical field and lead to more accurate diagnoses.
https://healthcare.boardofinnovation.com/glass-ai/